Back to announcement
20260326_OMED_Laporan Informasi dan Fakta Material_32055392_lamp3.pdf
Other Text extracted OMEDSource file signed link, expires in 15 minutes
Extracted text 2
Page 1
Solid 2025 Performance: OMED Records 9.4% Revenue Growth and
13.9% Increase in Net Profit
Surabaya, March 26, 2026
PT Jayamas Medica Industri Tbk (IDX: OMED) reported resilient financial performance in
fiscal year 2025, supported by revenue growth and stable profitability amid evolving healthcare
industry dynamics and persistent geopolitical headwinds.
OMED recorded net sales of IDR 2.06 trillion, representing a 9.4% year-on-year (YoY)
increase from IDR 1.89 trillion in 2024.
In line with revenue growth, gross profit rose 15.0% YoY to IDR 717.5 billion, with gross profit
margin improving to 34.8% from 33.1% previously. The margin expansion reflects production
cost efficiencies and an improved product mix toward higher-margin products.
OMED posted operating profit of IDR 390.9 billion, growing 12.2% YoY, while maintaining an
operating margin of 18.9%, reflecting stable cost management during the Company’s business
expansion.
Profit for the year increased 13.9% YoY to IDR 368.9 billion, compared with IDR 324.0 billion
in the previous year. Accordingly, earnings per share (EPS) rose to IDR 13.57 from IDR 11.89.
Operational Performance by Segment
Performance during the year was supported by growth across several key business segments:
1. Disposable medical and consumable products remained the largest contributor,
accounting for approximately 48.8% of total revenue, growing by 9.4% YoY.
2. The wound care segment recorded strong growth of 16.2% YoY, driven by higher sales
volumes and the launch of the new Isoplast product.
3. The antiseptic and dialysis segment grew 9.6% YoY, supported by increased sales
volumes and new product launches.
4. The biotechnology and laboratory segment posted the highest growth of 30.1% YoY.
5. The diagnostic and medical equipment segment experienced a 6.9% YoY adjustment
in line with market demand dynamics.
This performance reflects the stability of OMED’s business model, supported by a diversified
product portfolio and an extensive distribution network across Indonesia.
Page 2
2026 Outlook and Targets
Entering 2026, OMED maintains a constructive outlook on the growth prospects of the national
medical device industry despite global challenges such as geopolitical uncertainty and
potential energy price pressures.
OMED targets revenue of approximately IDR 2.3 trillion in 2026, representing projected growth
of 10–15% YoY. In addition, the Company aims to achieve:
1. Gross profit margin in the low-30% range
2. Export sales reaching USD 1.0–1.5 million
These targets will be supported by stronger domestic distribution, development of higher-
margin products, expansion into export markets, and continued operational efficiency
improvements.
For further information, please contact:
Corporate Secretary & Investor Relations PT Jayamas Medica Industri Tbk
Email : corporate.secretary@onemed.co.id
ir@onemed.co.id
Website : www.onemed.co.id
Names mentioned 1 people and organisations named in the text · linked when the evidence is strong
Extraction attempts how the parser did, and what it refused
Nothing structured was extracted from this document — the attempts below say why.
No extraction attempted yet.